SAHPRA in Crisis! Regulator is Failing its Mandate and Medical Cannabis Sector is Feeling the Pain

SAHPRA’s unilateral decision to halt approval of any further Section 21 medical cannabis applications has spiralled into a crisis. Patients are being denied access to medication and service providers face uncertainty while the regulator remains silent.

Section 21 Medical Cannabis Crisis Stakeholder Webinar

Join the Cannabis Crisis Committee and Cannabiz Africa on 29 October 2026 to shape a sector response urging SAHPRA to clarify medical cannabis access after halting Section 21 approvals.

The Case for Sun-Grown Cannabis

Sun grown cannabis is on the rise in the US as soaring input costs hit ‘indoor’, while ‘outdoor’ may foster a richer, more complex chemical profile.